---
title: "Genmab A/S：2025 年第三季度交易报告"
description: "北欧上市发行人报告 Genmab A/S：2025 年第三季度交易报告 Genmab A/S：2025 年第三季度交易报告 https://view.news.eu.nasdaq.com/view?id=bd2dc14f99b1c03244901a5d29bc9bea9&lang=en&src=omxlink"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/259911999.md"
published_at: "2025-10-03T15:53:55.000Z"
---

# Genmab A/S：2025 年第三季度交易报告

> 北欧上市发行人报告 Genmab A/S：2025 年第三季度交易报告 Genmab A/S：2025 年第三季度交易报告 https://view.news.eu.nasdaq.com/view?id=bd2dc14f99b1c03244901a5d29bc9bea9&lang=en&src=omxlink

北欧上市发行人报告

Genmab A/S：2025 年第三季度季度交易报告

Genmab A/S：2025 年第三季度季度交易报告 https://view.news.eu.nasdaq.com/view?id=bd2dc14f99b1c03244901a5d29bc9bea9&lang=en&src=omxlink

### Related Stocks

- [GMAB.US - Genmab](https://longbridge.com/zh-CN/quote/GMAB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| HC Wainwright bullish on Genmab A/S (GMAB) on robust sales for DARZALEX | H.C. Wainwright has reiterated a Buy rating on Genmab A/S (NASDAQ:GMAB) with a price target of $39, citing strong net sa | [Link](https://longbridge.com/zh-CN/news/275885478.md) |
| Genmab Reports 2025 DARZALEX Net Sales of USD 14.4 Billion | Genmab reported that its DARZALEX therapy achieved worldwide net sales of USD 14.351 billion in 2025, with USD 8.266 bil | [Link](https://longbridge.com/zh-CN/news/273231388.md) |
| Genmab reports top line results in Phase III DLBCL trial | Genmab has reported positive topline results from its Phase III EPCORE DLBCL-1 trial, demonstrating improved progression | [Link](https://longbridge.com/zh-CN/news/272966876.md) |
| AbbVie And Genmab: Phase 3 EPCORE DLBCL-1 Trial Shows PFS Gains But No Significant OS Benefit | AbbVie and Genmab announced results from the Phase 3 EPCORE DLBCL-1 trial, which evaluated epcoritamab in patients with  | [Link](https://longbridge.com/zh-CN/news/272890908.md) |
| Genmab Says Phase 3 Trial For Epcoritamab Did Not Reach Statistical Significance | Genmab A/S announced that its Phase 3 trial for Epcoritamab (Duobody® CD3XCD20) in patients with relapsed/refractory dif | [Link](https://longbridge.com/zh-CN/news/272868786.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。